Alcobra Ltd. Ord (ADHD) 4.01 $ADHD Alcobra Ltd. to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 10:16 AM

Alcobra Ltd. Ord (ADHD) 4.01 $ADHD

Alcobra Ltd. to Participate in Upcoming Investment Conferences
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3 Annual Healthcare Day.
ADHD: 4.01 (-0.09)

Alcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session
Zacks Equity Research - Zacks Investment Research - Fri May 20, 7:30AM CDT
Alcobra Ltd (ADHD) was a big mover last session, as the company saw its shares rise over 6% on the day.
ADHD: 4.01 (-0.09), JNP: 6.80 (-0.28)

The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
Zacks Equity Research - Zacks Investment Research - Mon May 16, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
SNDX: 11.44 (-0.08), EDIT: 26.80 (-1.55), ADHD: 4.01 (-0.09), MCRB: 29.00 (-1.37), NEOS: 9.11 (-0.54)

Alcobra reports 1Q loss
Automated Insights - Mon May 16, 7:15AM CDT
TEL AVIV, Israel (AP) _ Alcobra Ltd. (ADHD) on Monday reported a loss of $5.1 million in its first quarter.
ADHD: 4.01 (-0.09)

Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 16, 7:00AM CDT
-- Conference Call & Webcast May 16th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
ADHD: 4.01 (-0.09)

Drug Stocks' Earnings to Watch on May 16: ADHD, MCRB & More
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:26AM CDT
What's in store for drug stocks, Alcobra, Seres and others when they report their first-quarter results on May 16?
SNDX: 11.44 (-0.08), EDIT: 26.80 (-1.55), ADHD: 4.01 (-0.09), MCRB: 29.00 (-1.37), NEOS: 9.11 (-0.54)

Alcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call & Webcast on May 16
GlobeNewswire - Wed May 04, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter ended March 31, 2016 before the market open, and will host a corporate update conference call and webcast on Monday, May 16, at 8:30 am Eastern Time.
ADHD: 4.01 (-0.09)

MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 4.01 (-0.09), MEIP: 1.32 (-0.02)

Falling Earnings Estimates Signal Weakness Ahead for Valeant Pharmaceuticals (VRX)
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:53AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
VRX: 21.36 (-0.89), ADHD: 4.01 (-0.09)

Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.01 (-0.09), REPH: 7.85 (-0.09)

What Falling Estimates & Price Mean for Lannett (LCI)
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:40AM CDT
Lannett has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
LCI: 24.49 (-0.66), ADHD: 4.01 (-0.09)

Alcobra (ADHD) Sees Hammer Chart Pattern: Time to Buy?
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 5:34AM CDT
Alcobra Ltd. (ADHD) has been struggling lately, but the selling pressure may be coming to an end soon
ADHD: 4.01 (-0.09)

Grab These 4 Incredible Momentum Stocks for Less Than $10
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 9:10AM CDT
Momentum investing grants success to those who can effectively ride the upswing and brave the downswing of the market with the same elan.
PRMW: 10.64 (-0.25), ADHD: 4.01 (-0.09), VSLR: 2.97 (-0.13), MDXG: 7.66 (-0.27)

Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:00AM CDT
Ohr Pharmaceutical (OHRP) was a big mover last session, with its shares rising roughly 17% on the day.
ADHD: 4.01 (-0.09), OHRP: 2.63 (-0.11)

AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
PR Newswire - Tue Mar 29, 3:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen is an experienced and technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation. More recently he was interim CEO of Pearl Therapeutics which was subsequently acquired by Astra Zeneca for up to $1.15 billion in 2013. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra, Ltd. and two private biopharmaceutical companies.
ACRX: 2.61 (-0.12), GILD: 81.80 (-1.57), ADHD: 4.01 (-0.09)

Synergy Pharmaceuticals (SGYP) Jumps: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:00AM CDT
Synergy Pharmaceuticals (SGYP) was a big mover last session, with its shares rising over 6% on the day.
SGYP: 3.62 (-0.18), ADHD: 4.01 (-0.09)

Weakness Seen in Anacor Pharmaceuticals (ANAC) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 8:00AM CDT
Anacor Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ADHD: 4.01 (-0.09), ANAC: 99.06 (-0.14)

Ironwood's Q4 Loss Narrower than Expected, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 10:12AM CST
Ironwood Pharmaceuticals, Inc. (IRWD) reported a narrower-than-expected loss of 10 cents per share in the fourth quarter of 2015.
AGN: 227.93 (-5.58), IRWD: 12.44 (-0.51), ADHD: 4.01 (-0.09), PETX: 5.92 (-0.32)

New Strong Buy Stocks for February 19th
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
BLIN: 1.03 (-0.07), AMBR: 7.36 (-0.35), ADHD: 4.01 (-0.09), CPB: 62.43 (-0.21), BCO: 27.85 (-1.35)

ArQule (ARQL) Shows Strength: Stock Adds 7.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 7:15AM CST
ArQule Inc. (ARQL) shares rose almost 8% in the last trading session.
ADHD: 4.01 (-0.09), ARQL: 1.84 (-0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Protecting Your Family on Halloween: Safety Tips

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Ardelyx Securities Fraud Suit: Key Investor Moves

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...

CME Group Unveils First Baseball Futures Market

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Newfold Digital Revamps Leadership for Growth Surge

Steering into New Horizons with Fresh Leadership October 2026 marks a fresh chapter for Newfold Digital, as they shuffle the deck chairs a bit and ramp up for some ambitious growth endeavors. This web and commerce tech company decided it's time to bring a few heavy hitters on board. Starting this month, watch out for Sachin Puri taking the reins as Chief Executive...

Ajman Tourism Department Hits Internal Audit Milestone

A Nod to Standards in Ajman's Tourism Department Folks, it's not every day you see a government department get this kind of spotlight in the internal audit arena, yet here we are. The Ajman Department of Tourism, Culture and Media has snagged Full Conformance with Internal Audit Quality Standards. That’s not just some random feather in their cap but a signal flare in...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Rutter Mills Secures $13M in Virginia Injury Cases

The Stakes in Virginia When you drop nine successful injury cases on the scales and they tip over $13 million, that's a story worth dissecting. The two top dogs at Rutter Mills certainly know how to make a splash in the legal puddle, don't they? We're talking about attorneys Adam H. Lotkin and Georgina D. Montgomery here, the legal eagles behind these jaw-dropping...

Full Sail University Bags Billboard Music School Honor

Full Sail Scores a Billboard Nod — What's the Big Deal? Alright, Full Sail University just snagged a spot on Billboard Magazine's 2026 Top Music Business Schools list. That's no small fry, folks. This Florida institution has been carving out a niche in the music business education scene with a hands-on learning approach that hits the nail right on the head. The Recipe...